Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Jiangsu University, Zhenjiang, 212013, China.
BMC Complement Med Ther. 2020 Mar 23;20(1):96. doi: 10.1186/s12906-020-2874-0.
Frankincense and myrrh are used as traditional anti-inflammatory and analgesic medicines in China. It has been reported that frankincense and myrrh have significant anti-tumor activities. The present study was designed to investigate the inhibitory efficacy of frankincense ethanol extracts (RXC), myrrh ethanol extracts (MYC), frankincense -myrrh ethanol extracts (YDC), frankincense -myrrh water extracts (YDS) and their main compounds on U266 human multiple myeloma cell line.
The inhibition effects of cell proliferation was evaluated by MTT assays. Cell culture supernatant was collected for estimation of cytokines. Western blot analysis was designed to investigate the regulatory of JAK/STAT signal pathway. In addition, cell metabolomics based on the ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC/Q-TOF-MS) had been established to investigate the holistic efficacy of frankincense and myrrh on U266 cells. Acquired data were processed by partial least-squares discriminant analysis (PLS-DA) and orthogonal projection to latent structures squares-discriminant analysis (OPLS-DA) to identify potential biomarkers.
RXC, MYC significantly inhibited the proliferation of U266 cells at dose of 25-400 μg/mL, YDC and YDS at the dose of 12.5-400 μg/mL. 3-O-acetyl-α-boswellic acid, 3-acetyl-11 keto-boswellic acid and 11-keto-boswellic acid had the most significant anti- multiple myeloma activities in the 10 compounds investigated, therefore these 3 compounds were selected as representatives for Elisa assay and western blotting experiments. All the extracts and active compounds ameliorated the secretion of cytokines and down-regulated the expression of JAK/STAT signaling pathway-related proteins. Comparing RXC, MYC, YDC and YDS-treated U266 cells with vehicle control (DMSO), 13, 8, 7, 7 distinct metabolites and 2, 2, 3, 0 metabolic target pathways involved in amino acid metabolism, lipid metabolism, vitamin metabolism, arachidonic acid were identified, respectively.
Taken together our results suggest that the frankincense and myrrh and their bioactive compounds inhibit proliferation of U266 multiple myeloma cells by regulating JAK/STAT signaling pathway and cellular metabolic profile.
乳香和没药在中国被用作传统的抗炎和镇痛药物。据报道,乳香和没药具有显著的抗肿瘤活性。本研究旨在探讨乳香乙醇提取物(RXC)、没药乙醇提取物(MYC)、乳香-没药乙醇提取物(YDC)、乳香-没药水提取物(YDS)及其主要化合物对 U266 人多发性骨髓瘤细胞系的抑制作用。
通过 MTT 法评估细胞增殖抑制作用。收集细胞培养上清液,用于估计细胞因子。采用 Western blot 分析研究 JAK/STAT 信号通路的调节。此外,基于超高效液相色谱-四极杆飞行时间质谱(UPLC/Q-TOF-MS)的细胞代谢组学已建立,用于研究乳香和没药对 U266 细胞的整体疗效。通过偏最小二乘判别分析(PLS-DA)和正交投影到潜在结构平方判别分析(OPLS-DA)对获得的数据进行处理,以鉴定潜在的生物标志物。
RXC、MYC 在 25-400μg/ml 剂量下显著抑制 U266 细胞的增殖,YDC 和 YDS 在 12.5-400μg/ml 剂量下抑制 U266 细胞的增殖。在所研究的 10 种化合物中,3-O-乙酰-α-乳香酸、3-乙酰-11 酮基乳香酸和 11-酮基乳香酸具有最显著的抗多发性骨髓瘤活性,因此这 3 种化合物被选为 ELISA 检测和 Western blot 实验的代表。所有提取物和活性化合物均改善了细胞因子的分泌,并下调了 JAK/STAT 信号通路相关蛋白的表达。与 DMSO 对照相比,RXC、MYC、YDC 和 YDS 处理的 U266 细胞中有 13、8、7、7 个不同的代谢物和 2、2、3、0 个代谢靶点途径参与氨基酸代谢、脂质代谢、维生素代谢、花生四烯酸。
总之,我们的研究结果表明,乳香和没药及其生物活性化合物通过调节 JAK/STAT 信号通路和细胞代谢谱来抑制 U266 多发性骨髓瘤细胞的增殖。